{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T18:02:22Z","timestamp":1771437742196,"version":"3.50.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Jiangxi Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["20242BAB20426"],"award-info":[{"award-number":["20242BAB20426"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jiangxi Provincial Administration of Traditional Chinese Medicine Technology Program","award":["2021B363"],"award-info":[{"award-number":["2021B363"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Angiosarcoma is a rare, highly aggressive malignancy of vascular endothelial origin, marked by rapid local invasion and a high risk of distant spread. Radiation-associated disease is even rarer, and laryngeal involvement is scarcely reported. No standard therapy exists for locally advanced or metastatic cases, and clinical experience is limited. We report a case of radiation-associated laryngeal angiosarcoma and contextualize its diagnosis and management within the literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>The patient, a 31-year-old man, was admitted to the hospital, at January 24, 2022, due complaints of generalized bone pain, predominantly in the ribs and lumbar spine, worsening with coughing, along with hoarseness and episodes of choking while drinking, persisting for over 1 month.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Malignant tumor of the larynx (T3N0M1, stage IVc, AJCC 7th edition); bone metastatic malignancy; splenic metastatic disease; and history of nasopharyngeal carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Initial treatment with liposomal doxorubicin plus ifosfamide provided partial symptom relief. Genomic testing identified a TP53 mutation, and toripalimab with gemcitabine\/nab-paclitaxel produced a partial response lasting 9 months. After progression, sequential targeted agents (anlotinib, lenvatinib, bevacizumab, pazopanib) did not maintain disease control, and the patient died of progressive disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient died on October 5, 2024, due to respiratory failure, bone marrow suppression, and uncontrolled systemic pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Radiation-associated laryngeal angiosarcoma is exceptionally rare and portends a poor prognosis. This case illustrates the potential value of genomically informed multimodal therapy integrating chemotherapy, immunotherapy, and targeted agents; in our patient, toripalimab plus gemcitabine\/nab-paclitaxel achieved a 9-month partial response. Further studies are needed to establish evidence-based treatment strategies for this understudied disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046746","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:02:12Z","timestamp":1767711732000},"page":"e46746","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Multimodal treatment of radiation-associated laryngeal angiosarcoma: A case report and literature review"],"prefix":"10.1097","volume":"105","author":[{"given":"Yiyun","family":"Pan","sequence":"first","affiliation":[{"name":"Department of Oncology, Ganzhou Cancer Hospital, Ganzhou, Jiangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Ganzhou Cancer Hospital, Ganzhou, Jiangxi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Ganzhou Cancer Hospital, Ganzhou, Jiangxi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengkun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Ganzhou Cancer Hospital, Ganzhou, Jiangxi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8238-8624","authenticated-orcid":false,"given":"Wen","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, Ganzhou Cancer Hospital, Ganzhou, Jiangxi, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260218","first-page":"2303","article-title":"Angiosarcoma: a review of diagnosis and current treatment.","volume":"9","author":"Cao","year":"2019","journal-title":"Am J Cancer Res"},{"key":"R2-20260218","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijscr.2015.03.049","article-title":"Obscure gastrointestinal bleeding due to multifocal intestinal angiosarcoma.","volume":"10","author":"Navarro-Chagoya","year":"2015","journal-title":"Int J Surg Case Rep"},{"key":"R3-20260218","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/CCO.0000000000001147","article-title":"Medical treatment of angiosarcomas.","volume":"37","author":"Dufresne","year":"2025","journal-title":"Curr Opin Oncol"},{"key":"R4-20260218","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1308\/003588412X13171221588776","article-title":"Primary angiosarcoma of the larynx: a rare entity.","volume":"94","author":"Katna","year":"2012","journal-title":"Ann R Coll Surg Engl"},{"key":"R5-20260218","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.3390\/cancers14235938","article-title":"Immunological and genomic analysis reveals clinically relevant distinctions between angiosarcoma subgroups.","volume":"14","author":"van Ravensteijn","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R6-20260218","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1002\/cam4.1698","article-title":"Radiation-associated sarcoma after breast cancer in a nationwide population: increasing risk of angiosarcoma.","volume":"7","author":"Salminen","year":"2018","journal-title":"Cancer Med"},{"key":"R7-20260218","doi-asserted-by":"crossref","first-page":"627113","DOI":"10.3389\/fonc.2021.627113","article-title":"The effectiveness of different treatment modalities of cutaneous angiosarcoma: results from meta-analysis and observational data from SEER database.","volume":"11","author":"Bi","year":"2021","journal-title":"Front Oncol"},{"key":"R8-20260218","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1158\/1078-0432.CCR-25-0311","article-title":"Cemiplimab in locally advanced or metastatic secondary angiosarcomas (CEMangio): a phase II clinical trial and biomarker analyses.","volume":"31","author":"van Ravensteijn","year":"2025","journal-title":"Clin Cancer Res"},{"key":"R9-20260218","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1016\/j.ejca.2014.10.004","article-title":"First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.","volume":"50","author":"Young","year":"2014","journal-title":"Eur J Cancer"},{"key":"R10-20260218","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jamaoncol.2021.3547","article-title":"Efficacy and safety of TRC105 plus Pazopanib vs Pazopanib Alone for treatment of patients with advanced angiosarcoma: a randomized clinical trial.","volume":"8","author":"Jones","year":"2022","journal-title":"JAMA Oncol"},{"key":"R11-20260218","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","article-title":"Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.","volume":"26","author":"Penel","year":"2008","journal-title":"J Clin Oncol"},{"key":"R12-20260218","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2008.07.037","article-title":"Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.","volume":"44","author":"Schlemmer","year":"2008","journal-title":"Eur J Cancer"},{"key":"R13-20260218","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/annonc\/mdr066","article-title":"Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network.","volume":"23","author":"Stacchiotti","year":"2012","journal-title":"Ann Oncol"},{"key":"R14-20260218","doi-asserted-by":"crossref","first-page":"e002990","DOI":"10.1136\/jitc-2021-002990","article-title":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).","volume":"9","author":"Wagner","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"R15-20260218","doi-asserted-by":"crossref","first-page":"e004149","DOI":"10.1136\/jitc-2021-004149","article-title":"Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center.","volume":"10","author":"Rosenbaum","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"R16-20260218","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/cam4.5147","article-title":"Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: a multicenter, retrospective study.","volume":"12","author":"Watson","year":"2023","journal-title":"Cancer Med"},{"key":"R17-20260218","doi-asserted-by":"crossref","first-page":"596732","DOI":"10.3389\/fonc.2021.596732","article-title":"Efficacy of anlotinib for the treatment of angiosarcoma of the face and neck: a case report.","volume":"11","author":"Ren","year":"2021","journal-title":"Front Oncol"},{"key":"R18-20260218","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1186\/s12885-018-4828-1","article-title":"Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial.","volume":"18","author":"Lebellec","year":"2018","journal-title":"BMC Cancer"},{"key":"R19-20260218","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1158\/1078-0432.CCR-24-2519","article-title":"Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma.","volume":"30","author":"Movva","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R20-20260218","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"R21-20260218","doi-asserted-by":"crossref","first-page":"1090168","DOI":"10.3389\/fmed.2023.1090168","article-title":"Cutaneous angiosarcoma: a review of current evidence for treatment with checkpoint inhibitors.","volume":"10","author":"Guan","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R22-20260218","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/his.14433","article-title":"The impact of MYC gene amplification on the clinicopathological features and prognosis of radiation-associated angiosarcomas of the breast.","volume":"79","author":"Kuba","year":"2021","journal-title":"Histopathology"},{"key":"R23-20260218","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.immuni.2025.03.009","article-title":"More than the sum: how vascular endothelial growth factor inhibition unlocks the full potential of immune checkpoint blockade.","volume":"58","author":"Shu","year":"2025","journal-title":"Immunity"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:02:40Z","timestamp":1771434160000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046746","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"2025-08-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}